A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma

CONCLUSIONS: In this trial, treatment of newly diagnosed and recurrent glioblastoma with autologous dendritic cell vaccine pulsed with lysate derived from an allogeneic stem-like cell line was safe and well-tolerated. Clinical outcomes add to the body of evidence suggesting that immunotherapy plays a role in the treatment of glioblastoma.PMID:34862245 | DOI:10.1158/1078-0432.CCR-21-2867

Source: Cell Research - December 4, 2021 Category: Cytology Authors: Jethro L Hu Oluwaseun A Omofoye Jeremy D Rudnick Sungjin Kim Mourad Tighiouart Surasak Phuphanich Hongqiang Wang Mia Mazer Toni Ganaway Ray M Chu Chirag G Patil Keith L Black Stephen L Shiao Rong-Fu Wang John S Yu Source Type: research